Synergy CHC Secures Highly Dilutive $36M Equity Line of Credit and Issues Warrants Amidst Financial Distress

summarizeSummary

Synergy CHC Corp. secured a highly dilutive $36 million equity line of credit and issued warrants, a critical financing move for the financially distressed company, but at a significant cost to existing shareholders.

check_boxKey Events · Financing and Capital Events · SNYR

• Secured Equity Line of Credit

  The company entered into an equity purchase agreement with Hudson Global Ventures, LLC, allowing it to sell up to $36,000,000 of common stock over a 24-month period. This follows the S-3 registration filed 3 days ago on 2026-04-17 seeking shareholder approval for dilutive equity plans.

• Highly Dilutive Terms

  Shares will be sold at a variable discount, specifically 95% of the lesser of certain lowest traded or closing prices, which is highly dilutive for existing shareholders.

• Warrant Issuance

  As consideration for the agreement, the company issued a common stock purchase warrant for 1,540,000 shares at an exercise price of $0.01 per share, exercisable for five years. These warrants represent significant potential dilution.

• Shareholder Approval Required for Full Amount

  Issuance of shares under the agreement is limited by an "Exchange Cap" of 2,978,486 shares unless shareholder approval is obtained, meaning the majority of the $36 million facility is contingent on future shareholder action.

auto_awesomeAnalysis · SNYR · Life Sciences

This 8-K details a critical financing agreement for Synergy CHC Corp., a company facing severe financial challenges. The ability to raise up to $36 million through an equity line of credit (ELOC) provides a potential lifeline, especially given the recent term loan amendment requiring a $10 million equity raise by September 2026. However, the terms are highly unfavorable for existing shareholders, with shares to be sold at a discount to market prices. The issuance of 1,540,000 warrants at a nominal exercise price further exacerbates potential dilution. While the full $36 million is contingent on shareholder approval beyond an initial "Exchange Cap," this agreement signals the company's urgent need for capital and its willingness to accept highly dilutive terms to secure it. This event is a significant step in the company's ongoing efforts to address its liquidity issues and meet its debt obligations, but at a substantial cost to equity value.